Clinical trial
Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy
NCT00344617 · Singapore National Eye Centre, Other · Unknown status
Key facts
| NCT number | NCT00344617 |
|---|---|
| Title | Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy |
| Official title | Off-Label Use of AVASTIN (BEVACIZUMAB)Intravitreal Injection For the Treatment of Serosanguinous Maculopathy |
| Lead sponsor | Singapore National Eye Centre, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Choroidal Neovascularisation, Polypoidal Choroidal Vasculopathy |
| Intervention type | Drug |
| Interventions | Bevacizumab (tradename: Avastin) |
| Enrollment | 50 |
| Start date | Jun 1, 2006 |
| Completion | May 1, 2008 |
| First posted | Jun 27, 2006 |
| Last update posted | Sep 26, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: